Investor Presentaiton

Clarity's proprietary SAR Technology platform Theranostic radiopharmaceuticals have four main elements: a radioisotope, cage, linker and targeting ligand and are administered intravenously Tumour Tumour specific receptors Proteins expressed by cancer cells which the radiopharmaceuticals target Radioisotope Copper isotopes used, for example, in Positron Emission Tomography (PET) imaging (64Cu) or therapy (67Cu) Targeting molecule Finds and binds cancer cells in the body Linker Cage "Chelator" that securely holds radioisotopes That connects the cage to the targeting molecule Ⓒ CLARITY PHARMACEUTICALS SAR Technology platform A proprietary, highly specific and highly stable bifunctional cage (chelator) with a superior ability to retain copper isotopes within it and prevent their leakage into the body Unlike the current I generation of | radiopharmaceuticals, SAR products do not I require heating in I order to bind copper I to the cage CLARITY 2014 MEIE 5

View entire presentation